O
NVLN

OrbiMed’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

OrbiMed’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100,000
Closed -$350K – 158
2018
Q1 		$350K Hold
100,000
– – ﹤0.01% 139
2017
Q4 		$312K Hold
100,000
– – ﹤0.01% 131
2017
Q3 		$703K Hold
100,000
– – 0.01% 135
2017
Q2 		$923K Hold
100,000
– – 0.01% 130
2017
Q1 		$1.07M Hold
100,000
– – 0.01% 128
2016
Q4 		$842K Buy
+100,000
New +$886K 0.01% 125

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

OrbiMed's NVLN Position: Q2 2018 in Review

OrbiMed sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 100,000 shares — an estimated $350K sold.

OrbiMed first reported a position in NVLN in Q4 2016 and held it in 6 quarters. The position peaked at $1.07M in Q1 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • OrbiMed reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • OrbiMed sold 100,000 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $350K.
  • OrbiMed first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 6 quarters.
  • OrbiMed's Novelion Therapeutics Inc. Common Shares position peaked at $1.07M in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.